Login to Your Account



Pharma: Clinic Roundup


Friday, June 28, 2013
• Forest Laboratories Inc., of New York, reported top-line results from an eight-week pivotal Phase III trial of the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription